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Abstract
Tumours progress despite being infiltrated by tumour-specific effector T cells1. Tumours contain 
areas of cellular necrosis, which is associated with poor survival in a variety of cancers2. Here, we 
show that necrosis releases an intracellular ion, potassium, into the extracellular fluid of mouse 
and human tumours causing profound suppression of T cell effector function. We find that 
elevations in the extracellular potassium concentration [K+]e act to impair T cell receptor (TCR)-
driven Akt-mTOR phosphorylation and effector programmes, this potassium-mediated 
suppression of Akt-mTOR signalling and T cell function is dependent upon the activity of the 
serine/threonine phosphatase PP2A3,4. While the suppressive effect mediated by elevated [K+]e is 
independent of changes in plasma membrane potential (Vm), it does require an increase in 
intracellular potassium ([K+]i). Concordantly, ionic reprogramming of tumour-specific T cells 
through overexpression of the potassium channel Kv1.3 lowers [K+]i and improves effector 
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functions in vitro and in vivo. Consequently, Kv1.3 T cell overexpression enhances tumour 
clearance and survival of melanoma-bearing mice. These results uncover a previously undescribed 
ionic checkpoint blocking T cell function within tumours and identify new strategies for cancer 
immunotherapy.
The tumour microenvironment is characterized in part by rapidly dividing cancer cells 
competing for limited local resources5,6. These factors cause dense areas of cellular 
apoptosis and necrosis 2. Tumour necrosis is frequently associated with a poor prognosis2, 
an observation thought to be an epiphenomenon of aggressive underlying cancer biology. 
However, cellular necrosis is also known to alter the extracellular milieu and has been 
associated with the release of intracellular ions7 8. While tumour-specific T lymphocytes 
harbour reactivity against tumour antigens9, their function is often suppressed within 
tumours1. Whether local necrosis or consequent ionic derangement contributes to T cell 
dysfunction within tumours is unknown.
Multiple lines of investigation have demonstrated that intact ion transport is required for T 
cell function. Germline ablation of store-operated Ca2+efflux (SOCE) results in severe 
combined immunodeficiency (SCID) in humans10. Moreover, voltage-gated Ca2+ channels 
are essential for T cell function and survival11 and mutations in the Mg2+ channel MAGT1 
lead to human T cell immunodeficiency12. Moreover, overabundance of Na+ and Cl- 
promotes T cell pathogenicity and autoimmunity via the kinase SGK-113. Despite ions 
playing a key role in T cell function, their extracellular concentrations and consequence 
within tumours are poorly characterised.
We hypothesized that tumour cell death leads to a local ionic imbalance within the tumour 
microenvironment. To isolate native undiluted extracellular fluid within tumours, hereinafter 
tumour interstitial fluid (TIF), we utilized a centrifugation method14 as previously 
described6,15. This enabled us to compare the concentration of 5 principal ions within TIF 
of murine B16 melanoma or human tumours to that within serum. The concentration of 
potassium ([K+]) in TIF was elevated compared to serum within both murine and human 
tumours (Fig. 1a,b and Extended Data 1a) but not in extracellular fluid isolated from healthy 
tissues (Extended Data 1b). We also observed a correlation between TIF [K+] and the 
density of dying cells within murine B16 tumours (Fig. 1c). Additionally, experimental 
induction of cell death or apoptosis in tumour-derived cell lines increased extracellular 
potassium concentration ([K+]e) (Fig. 1d and Extended Data 1c,d). Thus, we conclude that 
the extracellular space within tumours contains elevated [K+]e that is associated with local 
cellular apoptosis and necrosis.
We next asked whether elevated [K+]e affects T cell function. We found a striking dose-
dependent suppression of TCR-induced cytokine production by isotonic elevations in [K+]e 
(Fig. 1e,f). Elevated [K+]e acted independent of tonicity, with other monovalent and divalent 
ions or inert osmolytes failing to induce similar suppression (Fig 1f,g and Extended Data 1e-
h). Elevated [K+]e functioned to acutely suppress T cell activation across a range of signal 
strengths (Extended Data 1i), in the presence or absence of co-stimulation (Extended Data 
1j), in a non-redundant fashion to tumour-associated co-inhibitory signals (Fig. 1h,i and 
Extended Data 2a-b), in CD4+ TH1 and TH17 effector subtypes (Extended Data 2c,d), and 
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had no effect on cellular viability (Extended Data 2e). We next isolated endogenous human 
neoantigen-specific TIL, identified as likely mediators of immunotherapy-induced tumour 
clearance9,16, and found IFN-γ production by these cells in response to their cognate 
neoepitope to be significantly attenuated by elevated [K+]e (Fig. 1j and Extended Data 2f,g). 
Elevated [K+]e also led to suppression of target-specific IFN-γ production by T cells 
genetically engineered with a cancer-germline antigen specific TCR17(Extended Data 2h). 
Thus, our data suggests that elevated [K+]e acutely limits the function of mouse and human 
T cells.
To understand the basis for this suppression of effector function, we explored the effect of 
elevated [K+]e on the molecular events driven by TCR engagement. To this end, we briefly 
activated FACS-purified murine CD8+ T cells in the presence or absence of elevated 
potassium and found that elevated [K+]e significantly restrained the expression of transcripts 
induced by TCR stimulation (Fig. 2a,b). Furthermore, gene-set enrichment analysis 
indicated that elevated [K+]e suppressed genes induced by TCR signalling, NF-κB 
activation, escape from anergy, adaptive immune response, and cytokine pathways 
(Supplementary Information 1). Collectively, these data suggest that intratumoural cell death 
produces elevated [K+]e concentrations which act to suppress TCR-driven effector 
programmes.
The observation that elevated [K+]e acutely suppressed TCR-driven transcriptional events 
led us to ask whether [K+]e could affect TCR-induced signal transduction pathways. Given 
the role of [K+]e in regulating plasma membrane potential18,19, we initially hypothesized 
that K+ acted to suppress TCR activation via induction of cellular membrane depolarization 
(increased Vm) with subsequent dissipation of the electromotive force driving Ca2+ entry. 
However, we could not detect any changes in TCR-induced Ca2+ flux in the presence of 
isotonic elevations in [K+]e employed in our experiments (40mM) (Fig. 2c and Extended 
Data 3a). Additionally, elevated [K+]e did not affect the phosphorylation of Zap70, Erk1/2, 
PLCγ1, or global tyrosine phosphorylation following TCR ligation (Fig. 2d and Extended 
Data 3b-c). However, elevated [K+]e did reduce TCR-induced phosphorylation of Akt and 
serine/threonine residues targeted by Akt (Fig. 2e-g and Extended Data 3d), including 
mTOR and the ribosomal protein S6 (Fig. 2f,g and Extended Data 3d). Suppression of Akt-
mTOR signalling by elevated [K+]e was appreciable at later time points (Extended Data 3e), 
not recapitulated by other osmolytes (Extended Data 4a), and apparent in conditions of 
hypertonic hyperkalaemia (Extended Data 4b). Consistent with a role in limiting Akt-mTOR 
activity20, elevated [K+]e inhibited TCR-induced nutrient consumption, (Extended Data 
4c,d), CD4+ polarization to effector-lineages (Extended Data 4e,f), and promoted the 
induction of Foxp3+ CD4+ T cells (Extended Data 4g). Taken together, we conclude that 
elevated [K+]e limits TCR-driven effector function via suppression of the Akt-mTOR 
pathway.
We next aimed to determine how elevated [K+]e suppresses TCR-induced Akt-mTOR 
phosphorylation. First, we hypothesised that elevated [K+]e inhibits PI3K activity. However, 
elevated [K+]e had no effect on TCR-induced PIP3 accumulation, (Fig. 2h), indicating that 
K+-mediated suppression of Akt signalling was downstream of PI3K activation. Regulation 
of Akt activity downstream of PI3K is carried out, in part, by serine/threonine phosphatases. 
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To interrogate cytokine production in the presence of elevated [K+]e we used a 
pharmacologic screening approach to determine whether selected compounds, including 
inhibitors of cellular phosphatases, might restore effector function in the presence of 
elevated [K+]e. Phosphatase-inhibitors contained within the screen are depicted in Fig. 3a. 
Notably, okadaic acid (OA), an inhibitor of the serine/threonine phosphatase PP2A21, 
significantly restored T cell function in the presence of elevated [K+]e.
Moreover, OA reversed the hypophosphorylation of Akt and S6 caused by elevated [K+]e 
(Fig. 3b and Extended Data 5a) in addition to restoring effector function (Fig. 3c and 
Extended Data 5b). Similarly, genetic disruption of PP2A function, via overexpression of a 
dominant negative isoform (PP2A_DN) or by short-hairpin mediated RNA interference 
against the PP2A subunit Ppp2r2d similarly rescued effector function in the presence of 
elevated [K+]e (Fig. 3c, Extended Data. 5c and 5d). Consistent with the mechanistic 
involvement of Akt-mTOR hypophosphorylation in the suppression of effector function 
mediated by elevated [K+]e, we found that T cells expressing a constitutively active form of 
Akt (Akt1-CA) exhibited resistance to the inhibitory effects of high [K+]e (Fig. 3c and 
Extended Data 5e). Thus, we conclude that elevations in [K+]e drive hypophosphorylation of 
the Akt-mTOR pathway in a PP2A-dependent manner.
We next aimed to determine the intracellular changes responsible for decreased Akt-mTOR 
phosphorylation and cytokine production in the presence of elevated [K+]e.
As potassium is the principal determinant of resting plasma membrane potential (Vm)18,19, 
we first asked whether increased Vm in the presence of elevated [K+]e provided the source 
of T cell suppression (Fig. 3d,e). To this end we tested whether modulation of Vm by other 
means in the presence of low [K+]e would result in analogous suppression of T cell function. 
We treated cells with the ionophore gramicidin, which increases Vm by forming pores in the 
plasma membrane permeable to both sodium and potassium (Fig. 3f-h). However, as 
gramicidin, in contrast to elevated [K+]e, increased IFN-γ production (Fig. 3i), we reasoned 
that suppression of T cell function by high [K+]e is independent of its effect on Vm and 
rather depends upon the concentration of intracellular potassium ([K+]i). Consistent with 
this hypothesis, elevated [K+]e raised [K+]i while gramicidin depleted [K+]i and reversed the 
suppressive effect induced by high [K+]e (Fig. 3j-m and Extended Data 6a-c). Additionally, 
other pharmacologic conditions that depleted intracellular K+ led to rescue of T cell function 
in the presence of elevated [K+]e (Fig. 3m and Extended Data 6d-k). Consistent with results 
in other cell types, we quantified the baseline [K+]i of T cells as 133.8 mM±3.3. Additions 
of 20 to 40 mM [K+]e increased [K+]i to 143 mM±4.5 and 153.2 mM±4.4, respectively 
(Extended Data 7a,b). While T cells chronically exposed to elevated [K+]e responded 
similarly to subsequent [K+]e changes as those cultured in control conditions (Extended 
Data 7c-f), brief exposure to ouabain, a pharmacologic agent that inhibits the Na+, K+ - 
ATPase, partially reversed elevations in [K+]i and T cell suppression in the presence of high 
[K+]e (Fig. 3m and Extended Data 6h-k). Taken together, these data suggest that elevated 
[K+]i in the presence of elevated extracellular concentrations may result from a combination 
of augmented Na+, K+ - ATPase function and a relative decrease in potassium ion flow per 
channel as the dynamically equilibrated chemical gradient between the intracellular and 
extracellular space, and the absolute reversal potential for potassium, is attenuated.
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Collectively, our findings suggested that enhancing T cell potassium efflux might increase T 
cell anti-tumour function. Prior investigations of T cell-intrinsic potassium transport, 
focusing on the voltage-gated potassium channel Kv1.3 (Kcna3) and the calcium-gated 
potassium channel KCa3.1 (Kcnn4), have described dynamic regulation of potassium 
transport in association with T cell activation and differentiation state22,23. Brief re-
stimulation of CD8+ effector cells in vitro (Fig. 2b) revealed acute upregulation of Kcna3 
mRNA in addition to dynamic expression of transcripts encoding potassium channels, 
pumps, and regulatory subunits (Supplementary Information 2). Due to its TCR-induced 
expression and previously described role in T cell function24, we hypothesized that enforced 
expression of Kcna3 may increase potassium efflux with a resultant increase in 
intratumoural T cell effector function. Indeed, we found that overexpression of Kcna3 
(Figure 4a,b) resulted in lower T cell [K+]i (Extended Data 8a) and imparted resistance to 
elevated [K+]e-mediated suppression (Extended Data 8b). Overexpression or pharmacologic 
activation of KCa3.1 produced a similar gain-of-function and resistance to K+ mediated 
suppression (Extended Data 8c-d).
To test whether augmented potassium efflux improved T cell function in vivo, we transferred 
TCR-transgenic Pmel-1 CD8+ T cells transduced with Kcna3, or a control retroviral 
construct, into B16 tumour-bearing mice. First, we noted that Kcna3 overexpression in TIL 
increased Akt-mTOR activation (Fig. 4c) and IFN-γ production within tumours (Fig. 4d) 
and following brief re-stimulation ex vivo (Extended Data 8e), without affecting T cell 
phenotype or number in response to viral infection (Extended Data 8f-g).
To extend our observations, we tested whether human TILs from multiple cancer types were 
supressed by elevated [K+]e, or alternative treatments that increase [K+]i, in a PP2A 
dependent manner. Consistently, we found that either elevated [K+]e or inhibition of 
endogenous potassium channels with Ba2+ increased [K+]i and suppressed effector function 
in a manner that also required intact PP2A function in human TILs (Fig. 4e and Extended 
Data 9a,b).
To test whether the gain-of-function observed as a result of Kcna3 overexpression resulted 
from increased ion transport, we generated a non-conducting “pore dead” construct 
(Kcna3_PD; W389F)25. Kcna3_PD failed to alter [K+]i, cytokine production in vitro (Fig. 
4f,g and Extended Data 9c), or effector function of transduced TILs (Extended Data 9d). 
Moreover, only intact Kcna3 resulted in enhanced tumour clearance and host survival (Fig. 
4h,i). Collectively, these results indicate that augmenting cellular potassium efflux can 
provide a means to increase the function of adoptively transferred T cells in tumours.
In this study, we have found that cell death within tumours is associated with elevated [K+]e 
at a level that leads to increased [K+]i within T cells, silencing of TCR-induced Akt-mTOR 
phosphorylation and decreased T cell effector function. While intact PP2A function was 
required for K+ mediated suppression of T cell function, K+ did not directly affect PP2A 
phosphatase activity (Extended Data 9e,f), implicating a functional intermediate. 
Interestingly, investigations into the function of PP2A have identified several endogenous 
small molecules and metabolites that can variably affect PP2A to increase or decrease its 
contextual function26,27. Future experiments will aim to define if [K+]i alters the 
Eil et al. Page 5









processing, localization, or abundance of metabolites that affect PP2A activity. These 
findings may also shed light on prior observations that changes in [K+]i regulate 
inflammasome activation in macrophages28 and can control cellular peptide and 
phospholipid processing29,30.
Finally, we found that elevated [K+]e suppresses T cell effector function and that anti-
tumour T cells reprogrammed to express the potassium transporter Kcna3 exhibited lower 
[K+]i and mediated enhanced effector function in vitro and in vivo. These data identify a 
novel tumour-induced ionic checkpoint acting upon T cell effector function (Extended Data 
10a-c) and that manipulating the intracellular ion concentration of anti-tumour T cells can 
augment disease clearance, with implications for immune-based therapies for cancer.
Materials & Methods (online)
Study Approval
Animal experiments were conducted with the approval of the NCI and NIAMS Animal Use 
and Care Committees. All NIH cancer patients providing human samples were enrolled in 
clinical trials approved by the NIH Clinical Center and NCI institutional review boards. 
Each patient signed an informed consent form and received a patient information form prior 
to participation
Mice and cell lines
Pmel-1 (B6.Cg-/Cy Tg [TcraTcrb] 8Rest/J), Rag2−/−, OT-II (B6.Cg-Tg 
(TcraTcrb)425Cbn/J), and C57BL/6 mice were obtained from the Jackson Laboratory. 
C57BL/6 male mice of 6-8 weeks of age were used as recipient hosts for adoptive transfer 
unless otherwise indicated. We crossed Pmel-1 with Ly5.1 mice (B6.SJL-PtprcaPepcb/BoyJ) 
to obtain Pmel-1 Ly5.1 mice. We crossed OT-II with Rag2-/- to obtain OT-II Rag-/- mice. All 
mice were maintained under specific pathogen–free conditions. B16 (H-2Db), a murine 
melanoma, transduced as previously described31 to express gp100 with human residues at 
position 25-27; EGS -> KVP. Mel624 was obtained from ATCC and Platinum-E ecotropic 
packaging cells were obtained from Cell Biolabs. Cell lines and maintained in DMEM 
media with 10% FBS, 1% glutamine and 1% penicillin-streptomycin.
Cell line authentication
Mel624 and Platinum-E cells were obtained from ATCC following authentication and 
validation as being mycoplasma free. Authenticated B16 was obtained from the National 
Cancer Institute Tumour Repository and validated as being mycoplasma free via a PCR 
based assay.
Statistical analysis
Data were compared using either a 2-tailed Student’s t test corrected for multiple 
comparisons by a Bonferroni adjustment or repeated measures 2-way ANOVA, as indicated. 
Where necessary, the Shapiro–Wilk test was used to test for normality of the underlying 
sample distribution. Experimental sample sizes were chosen using power calculations with 
preliminary experiments or were based on previous experience of variability in similar 
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experiments. Samples that had undergone technical failure during processing were excluded 
from analyses. The Kolmogorov–Smirnov test was used to evaluate the significance between 
different distributions. For adoptive transfer experiments, recipient mice were randomized 
prior to cell transfer. The products of perpendicular tumor diameters were plotted as the 
mean ± SEM for each data point, and tumor treatment graphs were compared by using the 
Wilcoxon rank sum test and analysis of animal survival assessed using a log-rank test. In all 
cases, P values of less than 0.05 were considered significant. Statistics were calculated using 
GraphPad Prism 7 software (GraphPad Software Inc.).
Electrolyte analysis of serum and interstitial fluid
We utilized a previously reported method to isolate tissue interstitial fluid via a 
centrifugation method6,15,14. Briefly, en bloc tissue was harvested, placed on triple layered 
10 µM nylon mesh, and spun at <50 g for 5 minutes to remove surface liquid. Next, samples 
were centrifuged at 400 g, a previously validated speed at which intracellular contents are 
not liberated15,14, for an additional 10 minutes. Flow through from this step was retained as 
interstitial fluid and assayed for indicated electrolyte concentrations in a blinded fashion 
within the NIH Central Clinical Chemistry Laboratory using auto analyzer (AA) ion 
selective electrode (ISE) quantification (Cobas 6000; US Diagnostics)32.
External Solution Formulations
Unless otherwise indicated, re-activation of cells in elevated concentrations of potassium 
([K+]e) was performed with an isotonic RMPI formulation with an additional 40 mM of 
potassium for mouse cells and 50 mM for human cells in comparison to the control 
condition media. In principal this media was produced by obtaining a custom formulation of 
RPI 1640 from Gibco that was devoid of NaCl. For control conditions, this media was 
reconstituted with NaCl to produce a solution equimolar to standard RPMI. Thus, the final 
inorganic salt concentrations for the control condition was identical to that in RPMI 1640 
(Gibco) in mM: NaCl 103.4, NaHC03 23.8, Na2PO4 5.6, KCl 5.3, MgSO4 0.4, Ca(NO3)2) 
0.4. For isotonic media containing an additional 40 mM KCl, this media was reconstituted 
with a combination of NaCl and KCl such that the final inorganic salt concentrations, again 
in mM, were: NaCl 63.4, NaHC03 23.8, Na2PO4 5.6, KCl 45.3, MgSO4 0.4, Ca(NO3)2) 0.4. 
For 40 mM hypertonic NaCl the final inorganic salt concentrations were, in mM: NaCl 
143.4, NaHC03 23.8, Na2PO4 5.6, KCl 5.3, MgSO4 0.4, Ca(NO3)2) 0.4. For 40 mM 
hypertonic KCl the final inorganic salt concentrations were, in mM: KCl 143.4, NaHC03 
23.8, Na2HPO4 5.6, KCl 5.3, MgSO4 0.4, Ca(NO3)2) 0.4. All other additives in RPMI 1640 
(Vitamins, amino acids, glutathione, phenol red, etc) were unchanged in quality or quantity.
T cell TCR-induced Ca2+ was carried out in a combination of NaCl deplete RPMI 1640 
reconstituted with NaCl or KCl and HBSS with Ca2+ and Mg2+ and without phenol red 
(Gibco). As such, the final inorganic salt concentrations in control conditions were, in mM: 
NaCl 120.6, NaHC03 13.9, Na2PO4 2.9, KCl 5.3, MgSO4 0.4, Ca(NO3)2) 0.2, CaCl2 0.63, 
KH2PO4 0.22, MgCl2 0.25, and D-glucose 8.3 mM. While in the same experiment the 
concentration of inorganic salts, in mM, in the condition with elevated [K+]e were: NaCl 
80.6, NaHC03 13.9, Na2PO4 2.9, KCl 45.3, MgSO4 0.4, Ca((NO3)2) 0.2, CaCl2 0.63, 
KH2PO4 0.22, MgCl2 0.25, D-glucose 8.3 mM. As this final solution was a combination of 
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HBSS and RPMI 1640 it contained all of the non-inorganic salt additives (vitamins, amino 
acids, glutathione, phenol red) normally within standard RPMI 1640, as reported in the 
publically available Gibco formulation, at one-half of the original concentration.
Generation and activation of effector T cells
In vitro activation of T cells was carried out either by negative enrichment (Miltenyi) of 
CD8+ T cells from C57BL/6 mice followed by activation using using immobilized anti-CD3 
(145-2C11; eBioscience) and anti-CD28 (37-51; eBioscience) along with expansion in 
culture medium containing IL-2 for 4-5 days, or via isolation of Pmel-1 Ly5.1 murine whole 
splenocytes followed by stimulation in vitro with 1 μM hgp10025–33 peptide and expansion 
in culture medium containing IL-2 for 4-5 days. For analysis of T cell effector function, 
these cells were then stimulated on day 4 or 5 of culture in the indicated conditions for 5 
hours with anti-CD3 and CD28 without IL-2 in the presence of brefeldin-A and monesin 
(BD Biosciences). For assaying co-inhibitory signalling, PD-L1 based co-inhibition PD-L1-
IgG2a (R&D) was conjugated along with anti-CD3 and anti-CD28 antibodies (eBioscience) 
and control IgG2a (R&D) onto M-450 Epoxy Dynabeads (ThermoFisher) at a ratio of (1 : 
1 : 2 : 6) for (anti-CD3 : anti-CD28 : PD-L1-IgG2a : IgG2a) for a total of 5 µg mL-1 protein 
per 2 x 106 beads overnight at 4°C. For comparative control conditions IgG2a was replaced 
for PD-L1 to control for bead loading. These beads were then incubated with effector CD8+ 
T cells at a ratio of 1:1 in the indicated conditions for 5 hours. For CTLA-4 based co-
inhibition, anti-CD3, anti-CD28, and CTLA-4-IgG2a (R&D) or IgG2a (R&D) were coated 
onto tissue culture treated 96-well plates at a concentration of 5 µg mL-1 (in a fashion 
similar to standard immobilized antibody based stimulation) for each reagent overnight at 
4°C. For assaying neoantigen specific reactivity, human TIL from NCI-14-C-0062, 
generated as described in section below, were re-activated for 5 hours with autologous pre-
activated B-cells that were pulsed with the indicated wild-type or neo-antigen peptides as 
described below. Transduced human peripheral blood lymphocytes were co-cultured with 
the A375 patient derived melanoma tumour line, HLA-A*0201+ and positive for NY-ESO-1 
expression33, at a ratio of 1 T cell to 3 tumour cells in the presence of brefeldin-A and 
monesin (BD Biosciences) for 5 hours. For analysis of human CD8+ TIL of varied 
histologies in the presence or absence of elevated K+ or Ba2+, TILs were first grown from 
tumour fragments cultured in 6000 IU mL-1 IL-2 in 1 to 1 mixture of RPMI 1640 and AIM-
V, supplemented with 5% in-house human serum, penicillin and 100 µg mL-1streptomycin, 2 
mM L-glutamine, 10 µg mL-1 gentamicin), antibody (Miltenyi Biotec) for approximately 14 
days per standard operating GMP protocols practiced by the Surgery Branch34. These T 
cells were then subjected to a rapid expansion protocol (REP) using irradiated PBMC at a 
ratio of 1 to 300 in in the same complete media with 30 ng mL-1 OKT3 in preparation for 
subsequent patient transfer, these cells were activated via immobilized anti-CD3 and anti-
CD28 in the presence of K+, Ba2+, and/ or OA as indicated. For experiments interrogating 
mouse CD4+ cells naïve were obtained by isolating splenocytes from 6-10 week old OT-II 
Rag-/- mice and subjected to negative selection of naïve CD4+ T cells (Stemcell 
Technolgies). These naïve cells were activated with immobilized anti-CD3 and anti-CD28 (5 
μg mL−1 each) in media for 2 days followed by an additional 2 days on blank plates with 
relevant polarizing cytokines present during the entire duration of the 4 day culture: Th1 
conditions (IL-12 10 ng mL-1 or as indicated, R&D Systems) Th17 conditions (IL-6 (20 ng 
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mL−1, R&D Systems), human TGF-β1 (1 ng mL−1, R&D Systems), anti-IFN-γ neutralizing 
antibodies (10 μg mL−1), IL-1β (10 ng mL-1), or iTreg conditions (human TGF-β1 200 pg 
mL−1) as indicated.
For selected experiments as indicated cells were treated with Okadaic Acid (OA) at a 
concentration of 200 nM (mouse CD8+ T cells) and 125 nM (human CD8+ TIL), Gramicidin 
(0.75 or 1.5µM), Ouabain 125µM (pre-incubated for 30 min), 1-EBIO (50µM), or 
Valinomycin (2µM).
RNA purification, quantitative real-time RT-PCR, RNA-sequencing and bioinformatic 
analysis
RNA sequencing was performed and analysed as described previously35. CD8+62L+ 
C57BL/6 splenocytes were FACS sorted from 6-8 week old mice in biological triplicate and 
activated with anti-CD3 and CD28 for 48 hours in IL-2 100 IU mL-1 and cultured in RPMI 
complete media for an additional 72 hours. Cells were then subjected to ficoll density 
separation to isolate live cells, placed in complete media without IL-2 in the presence or 
absence of elevated [K+]e, and either re-stimulated with anti-CD3 and CD28 or kept in 
complete media for two hours with no stimulation (No stim). Cellular RNA was preserved 
with RNAlater (Qiagen) and purified with the RNeasy Plus Mini Kit (Qiagen, Valencia, 
CA). RNA was subsequently used to prepare RNA-seq libraries by using TruSeq SRRNA 
sample prep kit (FC-122-1001, Illumina) according to the manufacturer’s instructions. The 
libraries were sequenced for 150bp (paired-end) using a NextSeq500 sequencer (Illumina). 
Sequence reads from each cDNA library were mapped onto the mouse genome build mm9 
by using Tophat, and the mapped data was then processed by Cufflinks36. The obtained data 
was normalized based on RPKM (reads per kilobase exon model per million mapped reads). 
To define differentially regulated genes, we used a 1.5-fold change difference between 
treatment groups. Real-time RT-PCR was performed for genes following cDNA generation 
by reverse transcription (Applied Biosystems) with primers from Applied Biosystems by 
Prism 7900HT (Applied Biosystems). RNA-sequencing raw data files are deposited at GEO-
GSE84996.
Extracellular Acidification Rate and Basal Oxygen Consumption Rate
OCR and ECAR were measured following re-stimulation of T cells using anti-CD3/28 
Dynabeads (Invitrogen) in a 0.8:1 ratio at 37°C using an XF24 extracellular analyzer 
(Seahorse Bioscience) as previously described37 in the indicated conditions. Oxygen 
consumption rates (OCR) and extracellular acidification rates (ECAR) were measured in XF 
media (nonbuffered RPMI 1640 containing 25 mM glucose, 2 mM L-glutamine, and 1 mM 
sodium pyruvate) in a 1:1 mixture with tonicity controlled additive free standard RPMI 1640 
with normal or elevated [K+] under basal conditions and in response to 1 μM oligomycin, 2 
μM fluoro-carbonyl cyanide phenylhydrazone (FCCP), or 100 nM rotenone with 1 μM 
antimycin A (Sigma).
Intracellular Cytokine Staining, PhosFlow, and flow cytometry
Suspensions containing T cells were stained with fixable live/dead (Invitrogen) in PBS 
followed by surface antibody staining in FACS buffer (PBS with 0.5% BSA and sodium 
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azide). For intracellular cytokine staining, cells were stained for intracellular molecules 
following fixation and permeabilization. For phosphostaining BD PhosFlow reagents were 
utilized and fixation/permeabilization protocols were carried according the to 
manufacturer’s protocol. After washing, cells were stained with antibody-fluorochrome 
conjugates for the indicated phosphorylated proteins (pZap70Y319 (BD Biosciences), all 
other phospho-antibodies were purchased from Cell Signaling). Antibodies for surface 
staining and intracellular cytokine staining were purchased from BD Biosciences and 
eBiosciences. For determination of cytoplasmic membrane potential (Vm) cells were 
incubated in 2uM DiSBAC43 (Invitrogen) in conditions as indicated for 60 minutes prior to 
evaluation. For determination of [K+]i, cells were loaded with the potassium sensitive dye 
Asante Green-4 (TEFLabs) with PowerLoad (Invitrogen) per the manufacturer’s protocols. 
All experiments were conducted on a BD Fortessa flow cytometer (Becton Dickinson) and 
analyzed with FlowJo software.
Identification and purification of mutation specific tumour infiltrating lymphocytes (TIL)
Cancer specific mutations and TIL targeted against those mutations from patients with 
metastatic melanoma were identified as previously described38. Briefly, patients were 
enrolled on a clinical protocol (NCI-14-C-0062). Whole-exomic sequencing (WES) was 
performed on tumour tissue and normal peripheral blood cells by Personal Genome 
Diagnostics (PGDx, Baltimore, MD) and the data was aligned to genome build hg18. A 
viable metastatic tumour deposit was selected for resection as a source for TIL. The resected 
en-bloc tumour was subjected to mechanical disruption via the GenlteMACS Dissociator. 
The bulk tumour digest was cultured in complete media without IL-2 or other cytokines 
overnight. The following day CD3+PD-1+ T cells were FACS sorted using a BD Jazz Flow 
cytometer. These sorted T cells were then subjected to a rapid expansion protocol (REP) 
using irradiated PBMC at a ratio of 1 to 300 in 50/50 medium (1 to 1 mixture of RPMI 1640 
and AIM-V, supplemented with 5% in-house human serum, 100 U mL-1penicillin and 100 
µg mL-1streptomycin, 2 mM L-glutamine, 10 µg mL-1gentamicin), 3000 IU mL-1of IL-2, 
and 30 ng mL-1of OKT3 antibody (Miltenyi Biotec) for approximately 14 days. At the 
conclusion of the first REP T cells were screened and FACS sort enriched with the BD Jazz 
sorter based on 41BB positivity38, against tandem mini-gene (TMG) constructs encoding 
for tumour specific mutations identified by WES for each patient and tumour, as described 
above and previously9,38,39. These enriched neo-antigen specific T cells were then 
expanded via a second REP. At the conclusion of the second REP T cells were activated with 
peptide pulsed (at 1 : 3; effector : target) autologous CD40L stimulated B-cells with either 
10 µg mL-1 of the full length 23-mer mutated or wild peptide (Patient A) or 1 µg mL-1 of the 
minimal epitope (Patient B,C) in the indicated conditions.
Retroviral transduction
Platinum-E ecotropic packaging cells (Cell Biolabs) were plated one day prior to 
transfections on poly-D-lysine coated 10cm plates (Corning) at a concentration of 6x106 
cells per plate. Packaging cells were transfected with 20µg of retroviral plasmid DNA 
encoding MSGV-Thy1.1, MSGV-Kcna3-Thy1.1, MSGV-Kcna3-Thy1.1 (W389F) (referred 
to as Kcna3_PD) 25, 40, MSGV-Ppp2r1a(K416E) -Thy1.1 (referred to as PP2A_DN41,42), 
MSCV-IRES-Thy1.1 (pMIT), or pMIT Akt1-CA43 where indicated along with 6µg pCL-
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Eco plasmid DNA using 60µL Lipofectamine 2000 in OptiMEM (Invitrogen) for 8 hours in 
antibiotic-free media. Media was replaced 8h after transfection and cells were incubated for 
a further 48 hours. Retroviral supernatants were then collected and spun at 2000g for 2 h at 
32°C onto 24 well non-tissue culture treated plates coated overnight in Retronectin (Takara 
Bio). For in vivo experiments live cells were isolated via ficoll density separation 
(Cedarlane) and subjected to positive-selection via CD90.1-microbead column enrichment 
according to the manufacturer’s protocol (Miltenyi) prior to transfer, yielding a CD8+ T cell 
population 70-95% Thy1.1+ prior to transfer. For retroviral transduction of human PBL with 
the NY-ESO-1 TCR, patients with metastatic melanoma on the clinical protocol NCI-13-
C-0214 were subjected to leukopheresis and their PBL were transduced with a MSGV1 
backbone encoding the NY-ESO-1 murine derived TCR as previously described17. After 
primary transduction and culture (10 days), these cells were then further expanded via a REP 
as described above (days 10-23) and subsequently assayed for target-specific effector 
function in the indicated conditions.
Adoptive cell transfer (ACT) and tumour immunotherapy
For immunotherapy, C57BL/6 were implanted with subcutaneous B16 melanoma (5 × 105 
cells). At the time of ACT, 10 days after tumour implantation, mice (n ≥ 5 for all groups) 
were sub-lethally irradiated (600 cGy), randomized, and injected intravenously with 5x10 5 
Pmel-1 Ly5.1 cells transduced with control or Kcna3 expressing retrovirus, and received 
intraperitoneal injections of IL-2 in PBS (6 × 104 IU/0.5 ml) once daily for 3 days starting 
on the day of cell transfer. Tumours were blindly measured using digital callipers. Tumour 
size was measured in a blinded fashion approximately every two days after transfer and 
tumour area was calculated as length x width of the tumour. Mice with tumours greater than 
400mm2 were euthanized. The products of the perpendicular tumour diameters are presented 
as mean ± SEM at the indicated times after ACT. For functional analysis of transferred 
Pmel-1cells, B16 tumour-bearing mice received Pmel-1 cells as above, and six to eight days 
following cell transfer mice were injected with 500 uL of 0.5 mg mL-1 brefeldin-A (Sigma) 
and six hours later tumours were harvested and processed for live/dead, surface, fixation, 
and intracellular staining for direct in vivo IFN-γ capture44. For ex vivo restimulation, 
tumours were harvested, processed as above, red cells were lysed with ACK lysis buffer for 
2 min at room temperature, then cell suspensions were subjected to live-cell isolation via 
ficoll density gradient separation (CedarLane) and stimulated in media containing Leukocyte 
activation cocktail with Golgiplug (BD biosciences) for 4 h at a final concentration of 2 µL 
mL-1.
Viral infection and kinetic analysis
For assessing the response of CD8+ T cells to acute viral infection, 5 × 105 transduced and 
Thy1.1+ enriched Pmel-1 Ly5.1 CD8+ T cells were transferred into recipient Thy1.2 Ly5.2 
C57BL/6 mice. Immediately following transfer, mice were infected with rhgp100 1 × 107 
plaque-forming units (PFU). At the indicated time points following transfer recipient mouse 
blood was obtained via sub-mandibular venipuncture and analysis for phenotype and 
enumeration of the congenically identified transferred cells.
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TCR crosslinking, western blots
As described previously45, to induce TCR crosslinking in vitro generated T cells were 
rested overnight in the absence of IL-2, subjected to live cell isolation via ficoll density 
gradient separation, pre-incubated with soluble anti-CD3 and anti-CD28-biotin, appropriate 
surface antibodies, and pharmacologic inhibitors where indicated in additive free RPMI 
1640 at 4°C. Cells were then washed, brought to 37°C, and stimulated via the addition of 
streptavidin in the indicated conditions. For western blots, at the indicated time points 
following cross-linking cells were lysed by the addition of 95°C 2x Laemmli sample buffer 
with 2-mercaptoethanol (Bio-Rad Laboratories) and sonicated for 40 seconds at 10% 
intensity prior to gel loading. For Kv1.3 protein analysis, Thy1.1+ enriched T cells were 
lysed in 1xRIPA buffer (Thermofischer) with protease and phosphatase inhibitors (Roche). 
Western blotting was performed using TGX reagents (Bio-Rad Laboratories) and protocols 
on PVDF paper. Following transfer blots were blocked with 5% BSA then incubated with 
antibodies against phospho-Tyrosine (4G10; EMD Millipore), pAkt-T308, Total Akt, β-
actin, Akt-substrate, or phospho-Threonine with appropriate HRP-conjugated or Alexa 647-
conjugated secondary antibodies (Cell Signaling Technology), anti-Kv1.3 (NeuroMab). For 
HRP-conjugated secondary antibodies blots were developed using chemiluminescence 
(Thermo Fisher Scientific), gel images were captured with the Gel Doc XRS (Bio-Rad 
Laboratories). For PI3K activity, cells were fixed at the indicated time points by the 1:1 
addition of a mixed lysis solution containing 30 mM HCl, 65% methanol, and 30% 
chloroform, maintained at -80°C then processed and analysed as previously described46.
TCR induced Calcium Influx
T cells were isolated and primed as above. Prior to analysis cells were ‘rested’ in IL-2 free 
complete RPMI 1640 for at least 8 hours. Cells were loaded with 1 μM Fluo3-AM and 1 μM 
Fura Red-AM (Invitrogen) for 30 min at 37°C in HBSS with Ca2+ and Mg2+ and 2% FCS, 
washed twice and then resuspended in HBSS with anti-CD3 and CD28-biotin conjugates 
(eBioscience) and live/dead (Invitrogen). For flow cytometry analysis, samples were 
resuspended in pre-warmed 37°C 1:1 mixtures of HBSS and isotonic normokalemic or 
hyperkalemic additive free RPMI (as described above in External Solution Formulations), a 
baseline measurement was recorded for 20 seconds, followed by the addition of Streptavidin 
(Invitrogen) to a final concentration of 20 µg mL-1 to induce TCR cross-linking and Ca2+ 
influx. Kinetic analyses were performed with the FlowJo software package (TreeStar).
shRNA mediated Ppp2r2d knockdown
A pLKO-Thy1.1 construct targeting Ppp2r2d was a generous gift of Dr.’s Zhou and 
Wucherpfenning and lentiviral particles were generated per their protocol4. BM cells were 
collected from the femurs and tibiae of 6-8 week old donor mice. After red blood cell lysis, 
hematopoietic stem and progenitor cells were enriched by autoMACS depletion of lineage 
positive cells using the Lineage Cell Depletion Kit (Miltenyi) for BM cells. Negatively 
selected cells were cultured in chemically defined serum free medium X-vivo 10 with 
Gentamicin (Lonza) supplemented with L-glutamine (1x) (Gibco), beta-mercaptoethanol 
(50mM), mouse recombinant SCF (50 ng mL-1), IL-6 (10 ng mL-1), IL-3 (5ng mL-1), 
FLT-3L (5ng mL-1) and IL- 7 (5ng mL-1) (Peprotech). The following day, these lineage 
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depleted BM cells were transduced by spin-infection at 32°C degrees 2000RPM for 90 
minutes in the presence of lentiviral supernatant and 5 µg mL-1polybrene (Sigma-Aldrich). 
Cells were incubated for another 2-4 hours prior to tail vein injection into Rag2-/- lethally 
irradiated (1000 cGy) recipient mice at 1-2 x 106 cells per mouse in 500 uL sterile PBS. 
CD8+Thy1.1+CD44+CD62L+ cells were FACS sorted 6-8 weeks following adoptive transfer, 
activated, and assayed as above.
PP2A Phosphatase Assay
PP2A activity was evaluated after immunoprecipitation utilizing a malachite green 
phosphatase assay kit as per the manufacturer’s instructions (EMD Millipore).
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Extended Data 1. Extracellular K+ release from apoptotic and necrotic cells inhibits T cell 
effector function
(a) Potassium concentration in TIF, RPMI, and mouse serum (b) Ratio of indicated ions in 
normal human tissue in comparison to serum measured on the day of tissue collection in 
cancer patients undergoing resection of nearby cancers originating from the same tissue 
type. (c) Representative flow cytometry plots of B16 melanoma tumour cells following the 
indicated treatment. (d) Extracellular [K+] quantification following the indicated treatment. 
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(e,f) Representative flow cytometry plots following anti-CD3/28 stimulated CD8+ T cells 
cultured in isotonic or hypertonic to RPMI in the indicated conditions (g) quantification of 
(f). (h) Quantification of cytokine production by CD8+T cells following stimulation in the 
indicated conditions, elevated Ca2+ and Mg2+ conditions equal to 2mM, in comparison to 
0.4 mM for control conditions. (i) Cytokine production by T cells across a titration of anti-
CD3 in the indicated conditions. (j) Representative flow cytometry plots and quantification 
following anti-CD3/CD28 titration based activation of CD8+ T cells in the indicated 
conditions. Error bars represent mean ± SEM. *P < 0.05; **P< 0.01 ***P < 0.001; ****P < 
0.0001 between selected relevant comparisons, 2-tailed Student’s t tests (a-d,h), 2-way 
ANOVA (g,i,j). (a) at least three biological replicates (b) five biological replicates (c,d) four 
experimental replicates (e-j) three culture replicates per condition. (c-j) Representative of at 
least two independent experiments.
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Extended Data 2. Potassium induced T cell suppression is functionally non-redundant to 
CTLA-4 and PD-L1 co-inhibitory signals and is present in TIL neoantigen responses.
(a-b) IFN-γ+ of CD8+ in the indicated conditions. (c) Flow cytometry analysis of cytokine 
production by CD4+ T cells polarized to under (c) TH1 or (d) TH17 conditions and 
subsequently re-activated via immobilized anti-CD3/28 in the indicated experimental 
conditions. (e) Annexin V and Propidium Iodide (PI) staining following activation of primed 
CD8+ T cells in the indicated conditions. (f) Representative flow cytometry plots and 
quantification of human neo-antigen selected TIL from 3 patients stimulated in the indicated 
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conditions with cognate mutated (mut) neo-antigen peptide pulsed target cells (autologous 
B-cells). (g) Relevant somatic mutation induced neoepitope for Pts. A-C in (f). (h) 
Representative flow cytometry and quantification of peripheral blood leukocytes from 3 
patients transduced with an HLA*A201 restricted NY-ESO-1 TCR were assayed in the 
indicated conditions for IFN-γ production. Additional [K+]e equal to 40 mM for (a-e) 
50mM for (f,h), three culture replicates per patient per data point, representative of two 
independent experiments. Error bars represent mean ± SEM. *P < 0.05; **P< 0.01 ***P < 
0.001; ****P < 0.0001, 2-tailed Student’s t tests (a-h). (a-h) At least three culture replicates 
per data point and representative of at least two independent experiments.
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Extended Data 3. Elevated [K+]e acts independently of TCR induced tyrosine phosphorylation 
and Ca2+ to suppress serine/threonine phosphorylation within the Akt-mTOR axis.
(a) Flow cytometry analysis TCR induced Ca2+ influx in the indicated conditions (AUC = 
area under the curve). (b) Flow cytometry analysis of TCR induced phosphorylation of the 
indicated phospho-residues in primed CD8+ T cells. (c) Immunoblot analysis of phospho-
tyrosine (4G10) residues from primed CD8+ T cells stimulated as above. For immunoblot 
source data see Supplementary Figure 1. (d) Flow cytometry analysis of CD8+ T Cells 
stimulated via TCR-crosslinking for the indicated phospho-residues and representative 
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histograms at early time points. Filled grey histograms represent unstimulated cells. (e) Flow 
cytometry analysis of the indicated phospho-proteins in CD8+ T cells stimulated at later time 
points following immobilized anti-CD3 and anti-CD28 stimulation in the indicated 
conditions. Elevated [K+]e equal to 40mM, isotonic. Error bars represent mean ± SEM. *P < 
0.05; **P< 0.01 ***P < 0.001; ****P < 0.0001 between selected relevant comparisons, 2-
tailed Student’s t tests (a,b), 2-way ANOVA (d,e). (a) Three biologic replicates per 
condition (b,d,e) three technical replicates per data point. Representative of (a-d) three or (e) 
two independent experiments.
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Extended Data 4. Elevated [K+]e suppression of TCR induced Akt-mTOR signalling limits 
activation induced nutrient consumption and T cell effector lineage commitment.
(a-b) Flow cytometry analysis of the indicated phospho-proteins in CD8+ T Cells stimulated 
via anti-CD3 and anti-CD28 cross-linking in the indicated conditions. (c) 2-NBDG uptake in 
primed CD8+ T cells induced by TCR stimulation in the indicated conditions with 
representative histograms and quantification. (d) Seahorse XF Bioflux analysis of CD3-28 
Dynabead induced extracellular acidification (ECAR) and oxygen consumption rate (OCR) 
of CD8+ T cells in the indicated conditions (e) Flow cytometry analysis of CD4+ T cells 
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polarized in the indicated experimental condition concurrently with (e) TH1, (f) TH17, or (g) 
iTreg cytokines. Elevated [K+]e equal to 40mM. Error bars represent mean ± SEM. *P < 
0.05; **P< 0.01 ***P < 0.001; ****P < 0.0001 between selected relevant comparisons, 2-
way ANOVA (a,b), 2-tailed Student’s t tests (c-g).Three technical or (c-g) culture replicates 
per data point. (a-g) Representative of two independent experiments.
Extended Data 5. Pharmacologic inhibition and genetic disruption of PP2A function restores T 
cell effector function in elevated [K+]e.
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(a) Flow cytometry analysis of the indicated phospho-proteins in primed CD8+ T cells 
stimulated via TCR-crosslinking in the indicated conditions. (b-c) Flow cytometry analysis 
of CD8+ T cell IFN-γ production following immobilized anti-CD3/28 and induced 
stimulation in the indicated conditions (b), or among cells expressing a PP2A_DN isoform 
(c). (d) Ppp2r2d gene expression in the indicated populations followed by flow cytometry 
analysis of IFN-γ production of the same. (e) Flow cytometry analysis of IFN-γ production 
by CD8+ T cells expressing an Akt1-CA isoform stimulated in the indicated conditions. 
Error bars represent mean ± SEM. *P < 0.05; **P< 0.01 ***P < 0.001; ****P < 0.0001 
between selected relevant comparisons 2-way ANOVA (a), 2-tailed Student’s t tests (b-e) 
where noted (a-e) additional [K+]e equal to 40mM, (a-e) three culture replicates per 
condition, (a-e) representative of at least two independent experiments.
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Extended Data 6. Depletion of intracellular potassium restores T cell cytokine production in the 
presence of elevated extracellular [K+].
(a,b) Intracellular [K+] of CD8+ T cells in the indicated conditions assayed via relative 
fluorescence of the potassium sensitive dye Asante-Green 4. (c) Flow cytometry analysis of 
IFN-γ production by primed CD8+ T cells following immobilized anti-CD3/28 based 
activation in the indicated conditions. (d) Plasma membrane potential (Vm) of CD8+ T cells 
in the indicated conditions assayed with the voltage-sensitive fluorescent indicator DiSBAC4 
(e) Relative intracellular [K+] of CD8+ T cells in the indicated conditions assayed with the 
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potassium sensitive dye Asante-Green 4. (f) Pictorial representation of the resultant 
intracellular changes in plasma membrane potential (Vm) and intracellular potassium 
concentration ([K+]i) in the presence of the ionophore Valinomycin. (g) Flow cytometry 
analysis of CD8+ T cells following immobilized anti-CD3/28 based re-activated in the 
indicated conditions. (h) Plasma membrane potential (Vm) of CD8+ T cells in the indicated 
conditions assayed with the voltage-sensitive fluorescent indicator DiSBAC4(3) (i) Relative 
intracellular [K+] of CD8+ T cells in the indicated conditions assayed with the potassium 
sensitive dye Asante-Green 4. (j) Pictorial representation of the resultant intracellular 
changes in plasma membrane potential (Vm) and intracellular potassium concentration 
([K+]i) in the presence of the Na+, K+ ATPase inhibitor Ouabain. (k) Flow cytometry 
analysis of CD8+ T cells following immobilized anti-CD3/28 based re-activated in the 
indicated conditions. Error bars represent mean ± SEM. *P < 0.05; **P< 0.01 ***P < 0.001; 
****P < 0.0001 between selected relevant comparisons 2-tailed Student’s t tests (c,g,k). 
Three technical (a,b,d,e,h,i) or culture (c,g,k) replicates per data point. (a-k) Representative 
of at least two independent experiments.
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Extended Data 7. Elevated [K+]e does not indelibly affect T cell intracellular [K+], membrane 
potential (Vm), or subsequent response to potassium induced suppression of effector function
(a) Flow cytometry based calibration for intracellular [K+]. For all values cells were treated 
with 50 µM Gramicidin in titrated doses of extracellular [K+] to provide a known 
intracellular [K+]. (b) Intra-experimental quantification of intracellular [K+] in control 
conditions and elevated extracellular [K+] as defined by calibration from (a). (c) Flow 
cytometry analysis of the relative plasma membrane potential (Vm) of CD8+ T cells of the 
indicated origin using the voltage-sensitive fluorescent indicator DiSBAC4(3) (d) cells of the 
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indicated origin assayed in the indicated conditions as in (c). (e) Flow cytometry analysis of 
relative intracellular [K+] of CD8+ T cells of the noted origin washed and assayed as 
indicated conditions quantified by relative fluorescence of the potassium sensitive dye 
Asante-Green 4. (f) Compiled analysis of relative IFN-γ production by CD8+ of the 
indicated origin washed and subjected to TCR stimulation in the indicated conditions. Error 
bars represent mean ± SEM. NS, not significant, between experimental and the control 
condition as assayed by 2-tailed Students t test (c) or 2-way ANOVA (d-f), for chronic 
conditioning additional [K+]e equal to 40mM, three (a-e) technical or (f) culture replicates 
per condition, (a-f) representative of two independent experiments.
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Extended Data 8. Enforced Kcna3 or Kcnn4 expression in CD8+ T cells augments effector 
function
(a) Flow cytometry analysis of CD8+ T cells retrovirally engineered with Ctrl-Thy1.1 or 
Kcna3-Thy1.1 encoding constructs assayed for relative intracellular [K+] quantified by 
relative fluorescence of the potassium sensitive dye Asante-Green 4. (b) Flow cytometry 
analysis of CD8+ T cells following re-activated in the indicated conditions. (c) Flow 
cytometry analysis of CD8+ T cells retrovirally engineering with Ctrl-Thy1.1, Kcna3-
Thy1.1, or Kcnn4-Thy1.1 encoding constructs and re-activated in the indicated conditions. 
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(d) Flow cytometry analysis of IFN-γ+ among CD8+ following re-activation in the indicated 
conditions (e). Flow cytometry analysis of Pmel-1 CD8+Thy1.1+ TIL IFN-γ+ production 6-8 
days after transfer into tumour bearing hosts following ex vivo re-activation. (f) Pmel-1 
CD8+ T cells retrovirally engineered with either Ctrl-Thy1.1 or Kcna3-Thy1.1 constructs 
and transferred into C57BL/6 hosts in conjunction with vv-hgp100 and quantified by cell 
number (f) or (g) surface phenotype found in the blood of recipients. Error bars represent 
mean ± SEM), 2-tailed Student’s t tests (a-d). 2-way ANOVA (f,g), NS, not significant, *P < 
0.05; **P< 0.01 ***P < 0.001; ****P < 0.0001. Three (a) technical or (b-d) culture 
replicates per condition. (e) seven mice per group (f,g) five mice per group. (a-g) 
Representative of two independent experiments.
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Extended Data 9. Elevated intracellular [K+] induced suppression of human CD8+ TIL effector 
function requires intact PP2A activity.
(a) Flow cytometry analysis of relative intracellular [K+] via the potassium sensitive 
fluorescent dye Asante-Green 4 of human CD8+ TIL in the indicated conditions. (b) 
Representative flow cytometry of the same cells in (a) following TCR based activation in the 
indicated conditions, quantification depicted in Fig. 4e. (c) Flow cytometry analysis of CD8+ 
T cells retrovirally engineered with either Ctrl-Thy1.1, Kcna3-Thy1.1, or Kcna3_PD - 
Thy1.1 encoding constructs. (d) Flow cytometry analysis of Thy1.1+ (transduced) Pmel-1 
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CD45.1+CD8+ TIL re-isolated 6 days following transfer into B16 melanoma-bearing mice 
and re-stimulated ex-vivo. Immunoprecipitated PP2A protein complexes isolated and 
assayed for relative phosphatase activity in (e) titrated concentrations of Okadaic acid or (f) 
the indicated conditions. Additional [K+]e equal to 40 mM for mouse cells and 50 mM for 
human cells unless otherwise indicated. Error bars represent mean ± SEM. NS, not 
significant between selected relevant comparisons, *P < 0.05; **P< 0.01 ***P < 0.001; 
****P < 0.0001, 2-tailed Student’s t tests (c,f). Three (a,e,f) technical or (b,c) culture 
replicates per condition. (d) Five mice per group. (a-f) Representative of two independent 
experiments.
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Extended Data 10. Intratumoural inhibition of T cell effector function via an ionic checkpoint.
(a) Healthy tissue contains limited local cellular decay, maintaining the interstitial [K+]e 
close to serum. T cells are robustly activated following TCR stimulation. (b) Tumour 
intrinsic phenomena produce a high density of cell death within cancers. Cell death leads to 
release of intracellular potassium into the extracellular space. The resultant elevated 
extracellular [K+] acts to increase the intracellular [K+] of T cells, limiting their activation 
and effector function. (c) Reduction of [K+]i and increased effector function can be imparted 
to tumour-specific T cells by over-expression of the potassium channel Kv1.3 (Kcna3).
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Figure 1. Elevated [K+] within tumour interstitial fluid (TIF) silences the TCR induced anti-
tumour function of mouse and human T cells
(a-b) Ratiometric representation of TIF to serum values for the indicated ions from mouse 
(a) and human (b) tumour tissue. (c) Linear regression and 95% CI best fit line representing 
the relationship between TIF [K+] and Annexin V+ cells per gram of tumour. Significance 
calculated by Pearson’s correlation coefficient. (d) Extracellular concentration of 
electrolytes following induction of cell death as indicated for mouse (left) and human (right) 
tumour cell lines. (e-i) Anti-CD3/28 based activation of CD8+ mouse T cells in the indicated 
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conditions with representative flow cytometry, additional [K+]e equal to 40mM unless 
otherwise indicated (e) and quantification (f-i). (j) Human TIL stimulated in the indicated 
conditions with mutated (mut) neo-antigen peptide pulsed target cells (autologous B-cells), 
additional [K+]e equal to 50 mM . Error bars represent mean ± SEM. *P < 0.05; **P< 0.01 
***P < 0.001; ****P < 0.0001 between selected relevant comparisons, (f,g) 2-way ANOVA, 
(h,i) 2-tailed Student’s t tests. (a,c) eighteen biological replicates (b) five biological 
replicates (d) four culture replicates (e-i) three culture replicates per condition (j) three 
culture replicates. Representative of (e-g) three (h,i,j) two independent experiments.
Eil et al. Page 36









Figure 2. Extracellular potassium inhibits TCR induced transcripts and function by suppressing 
Akt-mTOR phosphorylation
(a) Pie chart representing proportional subpopulations of all transcripts following 2h re-
stimulation of purified CD8+ T cells with anti-CD3/28 (b) Volcano plot of TCR induced 
genes briefly re-stimulated with anti CD3/28 in the indicated conditions. (c) TCR cross-
linking induced calcium flux of CD8+ cells as measured by Fluo3 / FuraRed fluorescence in 
the indicated conditions. (d) Representative phosflow cytometry plots following TCR cross-
linking in the indicated conditions. (e) Immunoblot analysis of the indicated phospho-
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residues in CD8+ T cells following TCR cross-linking (f) Quantitative phosflow analysis of 
cells activated as in (c) and (d) with representative flow cytometry in (g). (h) Quantification 
of the indicated phosphotidylinositol species in CD8+ T cells activated via TCR cross-
linking in the indicated conditions. Error bars represent mean ± SEM. *P < 0.05; **P< 0.01 
***P < 0.001; ****P < 0.0001 between selected relevant comparisons, 2-way ANOVA, (c-
h) where noted additional [K+]e equal to 40mM (a,b,c) three biological replicates (d,f) three 
technical replicates per data point (h) three experimental replicates with pooled analysis 
displayed, (d-g) representative of at least three independent experiments.
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Figure 3. Extracellular potassium mediated T cell suppression requires intact PP2A activity and 
is associated with elevations in intracellular potassium
(a) Selected phosphatase inhibitors from a pharmacologic screen for IFN-γ production of 
CD8+ T cells in the presence of elevated [K+]e, depicted as the ratio of IFN-γ expression in 
Ctrl / elevated [K+]e conditions in the presence of indicated phosphatase inhibitors (b) CD8+ 
T cell phosphorylation of pAktS473 and pS6S235/6 10 minutes following TCR cross-linking 
in the indicated conditions. (c) Compiled analysis of IFN-γ production by retrovirally 
transduced CD8+ Thy1.1+ T cells following TCR stimulation in the indicated conditions. (d) 
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Pictorial representation of the resultant intracellular changes in plasma membrane potential 
(Vm) and intracellular potassium concentration ([K+]i) in the presence of elevated 
extracellular potassium ([K+]e). (e) Relative cytoplasmic Vm of CD8+ T cells in the 
indicated conditions represented as relative fluorescence of the voltage-sensitive fluorescent 
indicator DiSBAC4(3). (f) Pictorial representation of the resultant intracellular changes in 
plasma membrane potential (Vm) and intracellular potassium concentration ([K+]i) in the 
presence of the ionophore gramicidin. (g) Relative cytoplasmic Vm of CD8+ T cells in the 
indicated conditions assayed as in (e) with representative flow cytometry in (h). (i) IFN-γ 
production by CD8+ T cells following TCR induced stimulation in the indicated conditions. 
(j) Representative flow cytometry representing [K+]i of CD8+ T cells as relative 
fluorescence of the potassium sensitive dye Asante-Green 4. (k) Relative [K+]i of CD8+ T 
cells in the indicated conditions assayed as relative fluorescence of the potassium sensitive 
dye Asante-Green 4. (l) Representative flow cytometry of cytokine expression by CD8+ T 
cells following TCR stimulation in the indicated conditions with compiled quantification in 
(m). Error bars represent mean ± SEM. *P < 0.05; **P< 0.01 ***P < 0.001; ****P < 0.0001 
between selected relevant comparisons, 2-tailed Student’s t tests (a-m), where noted 
additional [K+]e equal to 40mM, (a,c,i,l,m) at least three culture replicates per data point 
(e,g,h,j,k) three technical replicates per data point, representative of at least (a,b,c,m) two or 
(e,g,i,h,l,k) three or greater independent experiments.
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Figure 4. Kcna3 mediated augmented K+ efflux lowers intracellular [K+], enhances Akt-mTOR 
signalling, and augments anti-tumour effector function to improve tumour clearance and host 
survival.
(a) Pictorial representation of the potassium channel Kv1.3 (Kcna3) (b) Representative 
immunoblot analysis of Kv1.3 protein abundance in CD8+ Pmel-1 cells following retroviral 
transduction with Ctrl (Empty-Thy1.1) or Kcna3-Thy1.1 constructs. (c,d) Thy1.1+ Pmel-1 
CD45.1+CD8+ TIL 6-8 days following transfer into B16 melanoma-bearing mice were 
analysed for indicated phospho-residues (c) or in vivo IFN-γ production 6 hours after 
injection with Brefeldin A (d). (e) Relative cytokine expression of human TIL originating 
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from the indicated histology following TCR stimulation in the indicated conditions. (f,g) 
Analysis of intracellular [K+] (f) and representative flow cytometry for the expression of the 
indicated cytokines (g) of CD8+ Thy1.1+ T cells following transduction with retrovirus 
expressing Ctrl, Kcna3, or Kcna3_PD Thy1.1+ constructs. (h,i) Rates of tumour growth (h) 
and host survival (i) represented over time following receipt of Pmel-1 CD8+ T cells 
transduced as in (f,g). 2-tailed Student’s t tests (c-e), 2-way ANOVA (f), Wilcox rank-sum 
analysis (h), and Log-rank of Kaplan-meier survival estimates (i). Error bars represent mean 
± SEM. *P < 0.05; **P< 0.01 ***P < 0.001; ****P < 0.0001 between selected relevant 
comparisons, additional [K+]e equal to 50mM in (e). (c) five mice per group (d) seven mice 
per group (e) each symbol represents the mean of three culture replicates per patient per data 
point (f) three technical replicates per data point (h,i) at least ten mice per group, 
representative of (b) three, (c-i) two independent experiments.
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